Mitsubishi Published Study regarding Effect of Ingestion of Cysteine Peptide
Yield10 Bioscience and Mitsubishi Corporation Sign MOU to Evaluate the Establishment of a Partnership to Supply, Offtake and Market Camelina as a Feedstock Oil for Biofuel
Renewing its commitment to innovation in Japan and to Shonan Health Innovation Park (Shonan iPark), Japan-based Takeda Pharmaceutical has announced the creation of a new company, effective April 1, 2023, together with Industrial & Infrastructure Fund Investment (IIF) and Mitsubishi Corporation, to manage Shonan iPark.
PeptiGrowth Inc. is Launching A Novel Synthetic Peptide BMP4,7 inhibitor (Noggin-like peptide)
Cryoport, Inc., a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences including clinical research, pharmaceutical and cell and gene therapy markets, and Mitsubishi Logistics Corporation, a leading Japanese pharma logistics company, have announced a multi-year strategic business alliance to create an integrated regenerative medicine supply chain partnership in Japan.
Mitsubishi Heavy Industries Thermal Systems Ltd. (MHI Thermal Systems), a part of Mitsubishi Heavy Industries, Ltd. (MHI) Group in Japan, has confirmed its latest technology has the ability to remove and inactivate the novel coronavirus (SARS-CoV-2) by enzyme-urea formulation processing technology or irradiation by UV-C LED (ultraviolet-C light-emitting diode). Holding the potential to remove and inactivate airborne viruses with a unique air filer trapping innovation.
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of a new analysis examining real-world clinical outcomes of treatment with RADICAVA® (edaravone) in people with ALS at the 30th International Symposium on ALS/MND in Perth, Australia.
KOLKATA: Mitsubishi Corporation of Japan has agreed to invest Rs 100 crore in Sastasundar Healthbuddy, a digital healthcare platform with a mission to provide consistent access to affordable healthcare in a convenient manner.
Promethera Biosciences SA, a world-leading cell therapy and regenerative medicine company targeting liver diseases, today announced that it raised EUR 10 million (USD 11 million) in a Series C-extension financing. All major existing shareholders including Vesalius Biocapital, SRIW, Fund+, MGI Global Fund (Mitsui & Co), Boehringer Ingelheim Venture Fund and SMS Investments supported this round. New investors joining the financing round were Mitsubishi UFJ Capital Co., Ltd. and Cell Innovation Partners, L.P. (CIP) from Japan and LifeLiver Co., Ltd. from South Korea. The proceeds will be used to expand Promethera’s product development focus to include larger liver disease indications such as acute-on-chronic liver failure (ACLF), nonalcoholic steatohepatits (NASH) and Fibrosis and to accelerate these developments towards the clinic.